
Chiesi Completes the Acquisition of Three Hospital Products -- Kengreal(R), Cleviprex(R) and Argatroban(TM) for Injection
PARMA, ITALY--(Marketwired - June 22, 2016) - Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have finalized the acquisition of multinational rights to Kengreal® (cangrelor) for injection …